The most intriguing research, from a TNBC perspective, was conducted in Germany on 1,948 women with an average tumor size of 4 centimeters (about 1.6 inches). All received neoadjuvant chemotherapy of docetaxel, epirubicin and cyclophosphamide. Some were randomly assigned to receive Avastin.
Pathological complete response (pCR) was increased in the 663 women with TNBC who were given the Avastin.
• The pCR of those with TNBC who were not given Avastin was27.9 percent.